Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood
暂无分享,去创建一个
C. Lodigiani | P. Presbitero | M. Bacci | Z. Ruggeri | M. Marconi | E. Corrada | D. Zavalloni | G. Mendolicchio | L. Rota | G. L. MENDOLICCHIO
[1] P. Morange,et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. , 2010, Archives of cardiovascular diseases.
[2] J. Ferrières,et al. Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.
[3] K. Kent,et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. , 2009, The American journal of cardiology.
[4] N. Kleiman,et al. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. , 2009, The American journal of cardiology.
[5] S. Srinivasan,et al. The P2Y12 Antagonists, 2-Methylthioadenosine 5′-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-independent Increase in cAMP Levels* , 2009, The Journal of Biological Chemistry.
[6] E. Antman,et al. Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.
[7] F. Santilli,et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". , 2009, Journal of the American College of Cardiology.
[8] G. Montalescot,et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.
[9] Z. Ruggeri,et al. Platelet Adhesion under Flow , 2009, Microcirculation.
[10] J. Hirsh,et al. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future , 2008, Nature Clinical Practice Cardiovascular Medicine.
[11] M. Lordkipanidzé,et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. , 2008, European heart journal.
[12] S. Goto,et al. The challenge of monitoring platelet response after clopidogrel. , 2008, European Heart Journal.
[13] B. Giusti,et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function , 2008, Thrombosis and Haemostasis.
[14] A. Gori,et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. , 2008, Journal of the American College of Cardiology.
[15] Antiplatelet Therapy and Platelet Function Testing , 2008, Clinical cardiology.
[16] R. Blindt,et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis , 2007, Thrombosis and Haemostasis.
[17] P. Morange,et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome , 2007, Thrombosis and Haemostasis.
[18] O. Morel,et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis , 2007, Thrombosis and Haemostasis.
[19] J. Jukema,et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. , 2007, American heart journal.
[20] A. Gori,et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.
[21] S. Steinhubl,et al. Optimizing platelet P2Y12 inhibition for patients undergoing PCI. , 2007, Cardiovascular drug reviews.
[22] P. Gurbel,et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? , 2007, Journal of the American College of Cardiology.
[23] S. Goto,et al. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. , 2006, Journal of the American College of Cardiology.
[24] P. Gurbel,et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.
[25] R. Collins,et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[26] P. Théroux,et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. , 2005, Journal of the American College of Cardiology.
[27] O. Hess,et al. CLINICAL RESEARCH Interventional Cardiology Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy , 2005 .
[28] J. Geiger,et al. Monitoring of clopidogrel action: comparison of methods. , 2005, Clinical chemistry.
[29] C. Gachet,et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases , 2005, Journal of thrombosis and haemostasis : JTH.
[30] B. Jilma,et al. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA‐100 , 2004, Journal of thrombosis and haemostasis : JTH.
[31] Mario Mazzucato,et al. Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow. , 2004, Blood.
[32] Z. Ruggeri,et al. Signaling Through GP Ib-IX-V Activates αIIbβ3 Independently of Other Receptors , 2004 .
[33] C. Watala,et al. Limited usefulness of the PFA-100™ for the monitoring of ADP receptor antagonists–in vitro experience , 2004, Clinical chemistry and laboratory medicine.
[34] P. Conley,et al. Anticoagulants (Thrombin Inhibitors) and Aspirin Synergize With P2Y12 Receptor Antagonism in Thrombosis , 2003, Circulation.
[35] P. Conley,et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. , 2003, The Journal of clinical investigation.
[36] Zaverio M. Ruggeri,et al. Platelets in atherothrombosis , 2002, Nature Medicine.
[37] P. Nguyên,et al. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? , 2002, Thrombosis research.
[38] J. Moake,et al. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. , 2001, Blood.
[39] J. Seward,et al. The effectiveness of the varicella vaccine. , 2001, The New England journal of medicine.
[40] P. Conley,et al. Impaired activation of murine platelets lacking Gαi2 , 2001 .
[41] S. Goto,et al. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation , 2001, Platelets.
[42] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[43] U. Walter,et al. Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets , 1999, Thrombosis and Haemostasis.
[44] Z. Ruggeri,et al. HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Contribution of Distinct Adhesive Interactions to Platelet Aggregation in Flowing Blood , 1999 .
[45] Brian Savage,et al. Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow , 1998, Cell.
[46] M. Hadamitzky,et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.
[47] K. Titani,et al. A heparin-binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. , 1987, The Journal of biological chemistry.